- Home
- RIGL vs ISD Comparison
RIGL vs ISD Comparison
Compare RIGL & ISD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- ISD
- Stock Information
- Founded
- RIGL 1996
- ISD 2012
- Country
- RIGL United States
- ISD United States
- Employees
- RIGL N/A
- ISD N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- ISD Trusts Except Educational Religious and Charitable
- Sector
- RIGL Health Care
- ISD Finance
- Exchange
- RIGL Nasdaq
- ISD Nasdaq
- Market Cap
- RIGL 486.4M
- ISD 460.9M
- IPO Year
- RIGL 2000
- ISD N/A
- Fundamental
- Price
- RIGL $17.09
- ISD $13.60
- Analyst Decision
- RIGL Buy
- ISD
- Analyst Count
- RIGL 5
- ISD 0
- Target Price
- RIGL $34.80
- ISD N/A
- AVG Volume (30 Days)
- RIGL 203.8K
- ISD 127.1K
- Earning Date
- RIGL 11-07-2024
- ISD 01-01-0001
- Dividend Yield
- RIGL N/A
- ISD 9.69%
- EPS Growth
- RIGL N/A
- ISD N/A
- EPS
- RIGL 0.22
- ISD N/A
- Revenue
- RIGL $157,374,000.00
- ISD N/A
- Revenue This Year
- RIGL $48.98
- ISD N/A
- Revenue Next Year
- RIGL $14.43
- ISD N/A
- P/E Ratio
- RIGL $77.18
- ISD N/A
- Revenue Growth
- RIGL 21.65
- ISD N/A
- 52 Week Low
- RIGL $7.48
- ISD $10.98
- 52 Week High
- RIGL $29.82
- ISD $13.17
- Technical
- Relative Strength Index (RSI)
- RIGL 30.82
- ISD 34.61
- Support Level
- RIGL $16.68
- ISD $13.35
- Resistance Level
- RIGL $19.80
- ISD $14.31
- Average True Range (ATR)
- RIGL 1.53
- ISD 0.18
- MACD
- RIGL -1.05
- ISD -0.07
- Stochastic Oscillator
- RIGL 3.66
- ISD 16.67
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About ISD PGIM High Yield Bond Fund Inc.
PGIM High Yield Fund Inc is a diversified, closed-end management investment company, active in the financial services domain. The Fund's investment objective is to provide a high level of current income. It invests at least 80% of its investable assets in a diversified portfolio of high-yield fixed-income instruments that are rated below investment grade with varying maturities and other investments.